Wang, Zhijie <br/><br/>
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.  [electronic resource] 

 -  JAMA oncology  May 2019 
 - 696-702 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2374-2445 
<br/><br/><label>Standard No.: </label>10.1001/jamaoncol.2018.7098  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>B7-H1 Antigen--antagonists & inhibitors<br/>Biomarkers, Tumor--genetics<br/>Carcinoma, Non-Small-Cell Lung--blood<br/>Circulating Tumor DNA<br/>Female<br/>High-Throughput Nucleotide Sequencing<br/>Humans<br/>Immunotherapy<br/>Lung Neoplasms--blood<br/>Male<br/>Middle Aged<br/>Mutation<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors